ZIOPHARM Oncology

ZIOPHARM Oncology

Employees:
40
Market Cap:
$944.38 million
Revenue:
$6.93 million
5 Year Trend:
59.3%
Net Income:
$-127 million
NASDAQ:
ZIOP

ZIOPHARM Oncology is a publicly held, clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, that develops novel immunotherapies for the treatment of cancer. In 2011, ZIOPHARM established a partnership with Intrexon Corporation to develop and commercialize DNA-based cancer drugs based on Intrexons synthetic biology technology platform. Wikipedia

ZIOPHARM Oncology

Employees:
40
Market Cap:
$944.38 million
Revenue:
$6.93 million
5 Year Trend:
59.3%
Net Income:
$-127 million
NASDAQ:
ZIOP

ZIOPHARM Oncology is a publicly held, clinical-stage biopharmaceutical company headquartered in Boston, Massachusetts, that develops novel immunotherapies for the treatment of cancer. In 2011, ZIOPHARM established a partnership with Intrexon Corporation to develop and commercialize DNA-based cancer drugs based on Intrexons synthetic biology technology platform. Wikipedia